StalkMedium
TRVI remains in a medium-term bullish advance with clear higher highs and higher lows since late May. Price has pulled back into the intermediate EMAs and near horizontal support, offering a deferred entry opportunity. Short-term conditions are neutral without signs of exhaustion, so patience is warranted until acceptance at the EMAs. The long-term trend stays intact above major moving averages, while the key risk is a break below the 50 SMA and support area that would invalidate the bullish bias.
- ↑Phase IIa River Trial delivered 57% placebo-adjusted cough reduction (p<0.0001).
- ↑Maintained $172M cash at Q1 2026, funding trials through 2030.
- ↓Reported Q1 2026 net loss of $11.8M, reflecting steep cash burn.
Full analysis →